Organs-on-chips Market Analysis

Organs-on-chips Market Analysis

To get key market trends

  Download Free Sample

Based on the type, the global organs-on-chips market is classified into product and service. The product segment is expected to dominate contributing significantly to revenue of USD 81.3 million in 2023 and poised to exhibit dominance throughout the forecast period.

• The product segment is further sub-segmented into liver-on-chip, lung-on-chip, heart-on-chip, kidney-on-chip, and other organ chips.

   

• The lung-on-chip secured a substantial market share, driven by increased demand during the pandemic due to its applications. The precise prediction of airborne nanoparticle absorption and accurate replication of the inflammatory response to microbial pathogens showcased the widespread adoption for the lung-on-chip model.

   

• Furthermore, the global prevalence of pulmonary diseases, especially tuberculosis, has surged the demand for effective disease management, contributing to market growth. According to the WHO Global Tuberculosis Report 2022, around 10.6 million tuberculosis cases were found in 2021 worldwide, with a predicted 3.6% increase from 2020 to 2021.The surged demand for tuberculosis management through organ-on-chip technology is expected to fuel the market expansion.

Based on material, the organ on chip market is classified into polydimethylsiloxane (PDMS), polymer, and glass. The PDMS is expected hold the highest market share of 46.2% in 2023.

• The microfluidic organ-on-chip platform using PDMS has rapidly gained popularity and widespread adoption owing to its compatibility with high-resolution microstructures and nanostructures through replica molding.

   

• In addition, PDMS has been widely recognized for its biocompatibility, optical transparency, and gas permeability, making it well-suited for biological applications. Its elasticity also facilitated effective mechanical stimulation of cells witnessing as a promising tool for the next generation in-vitro models.

Based on model type, the organs-on-chips market is classified into single-organ model and multi-organ model. In 2023, the single-organ model dominated the market anticipating its growth during the analysis period with a CAGR of 32%.

• The popularity of single-organ models in the market is attributed to their specificity and focused applications. These models include liver-on-chip, lung-on-chip, heart-on-chip, and other chips provide comprehensive insights into specific organ functions, proving influential in drug development, disease modeling, and other applications.

   

• The single-organ model maintained the capability to replicate organ-level responses in a controlled environment, leading to the widespread adoption witnessing its dominance in driving advancements in organ-on-chip technology.

   

Based on applications, the organs-on-chips market is categorized into drug discovery, toxicity testing, disease modelling, personalized medicine, and other applications. The drug discovery is expected to lead the market, projecting the highest revenue of USD 476.8 million by 2032.

• The challenges in novel drug discovery, characterized by rising R&D costs and a low success rate in clinical trials, spurred the demand for advanced and precise predictive preclinical in-vitro models.

   

• Prominent market players are strategically advancing organ-on-chip technology to address the demand for cost-effective processes and explore market opportunities. For instance, in October 2023, Harvard University's Wyss Institute partnered with the Biomedical Advanced Research and Development Authority (BARDA) to elevate the human organ chip platform, with a focus on its potential in radiation exposure research. This strategic collaboration aimed in enhancing the research capabilities, secured funding support, and accelerated the drug discovery.

   

Based on end-user, the organs-on-chips market is classified into pharmaceutical and biotechnology companies, academic and research institutes, and other end-users. The pharmaceutical and biotechnology companies segment is held the highest market share of 63% in 2023.

• The pharmaceutical and biotechnology companies are actively seeking innovative solutions to bridge the translational gap between preclinical and clinical drug development, aiming to reduce attrition rates.

   

• The companies are leading in substantial investments, prioritize R&D, focused on personalized medicine, and consistently new product launches. Their focus on enhancing preclinical testing efficiency aligned with the market's demand for advanced and predictive in-vitro models.

   

• For instance, in September 2020, Javelin Biotech entered into a three-year collaboration with Pfizer Inc. to develop an innovative "Organ-on-a-Chip" predictive pharmacokinetics platform. The integrated platform aimed in accelerating the study of pharmacokinetic properties for small molecules using cutting-edge technology.

In 2023, North America secured a substantial market share in the organs-on-chips market and is expected to dominate throughout the forecast period.

• The dominance is boosted by escalated R&D expenditures in drug discovery and biotechnology in addition to the key market players presence and government initiatives.

   

• Additionally, the rising prevalence of chronic diseases is a driving factor. For instance, in June 2023, the FDA granted a partial option award to further propel the development of organ chips for radiation countermeasure research, evaluating efficacy and screening experimental compounds for Medical Countermeasures (MCM). Similarly, in 2021, responding to the COVID-19 pandemic, the FDA collaborated with the National Institute of Allergy and Infectious Diseases (NIAID) to advance organ-on-chip and microphysiological systems (MPS) models. This collaboration aimed in facilitating the development and assessment of Medical Countermeasures (MCMs) for COVID-19.

   

• Furthermore, growing investments by the public and private institutes, exemplified by the National Institutes of Health (NIH) funding for biotechnology, signified the continuous growth trajectory. In 2021, NIH estimated research funding for biotechnology in the U.S. at USD 7,847 million, projected to increase to USD 8,142 million in 2022. This upward trend in research funding anticipated a sustained growth, supporting organ-on-chip technology research and propelling market expansion in the foreseeable future.